Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.66% | -10.53% | 2.73% | 23.56% | 49.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.24% | 29.72% | 33.80% | 25.36% | 16.93% |
| Operating Income | -26.24% | -29.72% | -33.80% | -25.36% | -16.93% |
| Income Before Tax | -74.93% | -40.05% | -10.06% | 1.57% | 13.29% |
| Income Tax Expenses | -- | -- | -- | 79.94% | 45.88% |
| Earnings from Continuing Operations | -96.14% | -76.56% | -55.37% | -22.20% | 6.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.14% | -76.56% | -55.37% | -22.20% | 6.46% |
| EBIT | -26.24% | -29.72% | -33.80% | -25.36% | -16.93% |
| EBITDA | -26.22% | -29.73% | -33.82% | -25.38% | -16.95% |
| EPS Basic | -79.23% | -59.95% | -40.14% | -9.99% | 14.97% |
| Normalized Basic EPS | -25.89% | -26.64% | -27.46% | -17.41% | -7.47% |
| EPS Diluted | -79.23% | -59.95% | -40.14% | -9.99% | 14.97% |
| Normalized Diluted EPS | -25.89% | -26.64% | -27.46% | -17.41% | -7.47% |
| Average Basic Shares Outstanding | 9.05% | 9.94% | 10.88% | 10.62% | 10.35% |
| Average Diluted Shares Outstanding | 9.05% | 9.94% | 10.88% | 10.62% | 10.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |